Yunnan Baiyao Group (000538) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 was ¥9.40 billion, down 0.66% year-over-year; YTD revenue reached ¥30.65 billion, up 2.47% year-over-year.

• Net profit attributable to shareholders for Q3 was ¥1.14 billion, up 0.55% year-over-year; YTD net profit was ¥4.78 billion, up 10.41% year-over-year.

• Industrial revenue for the first three quarters was ¥11.58 billion, up 8.48% year-over-year.

Financial highlights

• Gross margin and operating profit improved, with basic and diluted EPS at ¥2.68 YTD, up 10.74% year-over-year.

• Net cash flow from operating activities was ¥4.46 billion for Q3, up 9.40% year-over-year.

• Total assets at period end were ¥53.34 billion, up 0.81% from year-end 2024.

• Shareholders’ equity reached ¥39.73 billion, up 2.32% from year-end 2024.

Outlook and guidance

• The acquisition of An Guo Shi Ju Yao Tang is expected to enhance the company’s national market presence and improve the efficiency of the traditional Chinese medicine supply chain.

• Integration of new subsidiaries and expanded product lines are anticipated to support future revenue and profit growth.